Evvy, a female-founded biotech startup, has published peer-reviewed validation for its Vaginal Health Test and presented new findings at multiple clinical conferences.
The validation study, published in the Diagnostics journal, analyzed over 7,000 vaginal microbiome samples using Evvy’s CLIA, CAP, and CLEP-certified Vaginal Health Test. The results demonstrated a sensitivity of 93.1 percent and specificity of 90 percent across more than 700 microbial species. Evvy’s test uses shotgun metagenomic sequencing to analyze over 700 species of bacteria and fungi from a single, at-home swab.
Over the past year, Evvy has presented research findings at three clinical conferences focused on vaginal health. At the Infectious Disease Society of ObGyn 2023, they reported a correlation between the presence of aerobes in vaginitis patients and increased symptom severity. They also identified variations in pathogenicity genes within Gardnerella genomes in the vaginal microbiome.
At the International Society of Women’s Sexual Health 2024 conference, Evvy’s research showed differences in vaginal microbiome profiles between menopausal and reproductive-age women who report pain during sex. The International Society for the Study of Vulvovaginal Diseases 2024 conference saw the company present findings indicating that Candida albicans can be present in women with high relative abundance of Lactobacillus, with or without symptoms.
Evvy also addressed vaginal odor at the Infectious Disease Society of ObGyn 2024 conference, presenting data linking specific microorganisms to increased incidence of this common concern.
Priyanka Jain, CEO and Co-Founder of Evvy, stated: “As shown by our robust validation and novel discoveries, we’re entering a pivotal era for Evvy as we elevate the standards of women’s healthcare through precision science.”
Evvy has also appointed Dr. Kate McLean, MD, MPH, FACOG as the company’s first Chief Medical Officer, reinforcing their commitment to advancing women’s health research and care. McLean commented: “As an OBGYN, I’ve seen up close how the lack of research in women’s health profoundly affects patient outcomes worldwide. As a healthtech leader, I’ve also seen the transformative power of technology and data to gather data, personalize care, and change lives at scale. I’m excited to join Evvy, the clear leader in transforming women’s health through data. Together, we will continue to empower patients and clinicians with comprehensive insights, while pushing the boundaries of scientific discovery to improve outcomes in fertility, pregnancy, gynecological cancers, menopause, and beyond.”
